Description and Prognostic Evaluation of Four Biological Parameters of Blast Cells in Adult Acute Lymphoblastic Leukemia
Recruitment status was: Recruiting
Adult acute lymphoblastic leukemia treatment approaches relie on risk stratification, including cytogenetics. We want to study at diagnosis several blast cells parameters on frozen samples of GRAALL protocols enrolled patients:
- A CD45-DNA double staining analysed by flow cytometry will allow mesurement for each blastic clone of DNA ploidy, percentage of cells in S-phase, CD45 fluorescence index.
- The proteine P16 metabolic way, involved in cell cycle regulation, will be studied by Western Blot analysis.
The comparison between these parameters, and main haematological data, will be followed by a prognostic analysis, based on blast corticosensibility in vivo, chimiosensibility, complete remission, and survival.
Combination of the studied parameters will allow to appreciate a clonal diversity. This will help to predict, at diagnosis, high probability of resistance to treatment.
Adult Acute Lymphoblastic Leukemia
Procedure: DNA Index
Procedure: CD45 expression
Procedure: P16 metabolic way
|Study Design:||Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
|Official Title:||Analysis of Four Biological Parameters at Diagnosis of Adult Acute Lymphoblastic Leukaemia: DNA Index, Percentage of Cells in S-Phase, CD45 Fluorescence Index, and Protein P16: Prognostic Study in Patients Enrolled in a Multicentric Trial|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00188084
|Contact: Agnès F CHASSEVENT, PhD||33-(0)firstname.lastname@example.org|
|CRLCC Centre Paul Papin||Recruiting|
|Angers, France, 49933|
|Contact: Agnès F CHASSEVENT, PhD 33-(0)2-41-35-27-00 email@example.com|
|Sub-Investigator: Mathilde HUNAULT-BERGER, MD,PhD|
|Sub-Investigator: Martine FFrench, MD,PhD|
|Sub-Investigator: Marina Lafage-Pochitaloff, MD,PhD|
|Sub-Investigator: Françoise HUGUET, MD|
|Principal Investigator:||Laurence M Baranger, MD||University Hospital, Angers|